Capitalizing on our 20-plus years of experience, we’ve assembled the right combination of expertise and infrastructure to drive non-viral drug product manufacturing. From formulation and aseptic filling to stability testing and final packaging, our comprehensive portfolio of services is designed to align distinctly to your needs. Put simply, we can go to work how, where, and when you need us.
That flexibility particularly shines as we take on a broad range of non-viral production initiatives, including:
- Filling viscous and non-viscous solutions/suspensions
- Handling of products with stability challenges, such as sensitivity to light or oxygen
- Lyophilization development, optimization, and commercialization of vials
- Component variety: vials, pre-filled syringes, and cartridges
Our Commitment to Investing in Non-Viral Drug Product Manufacturing
Our 87,000-sq. ft. Camden facility in Baltimore, Md., provides a high-quality aseptic filling operation with three ISO 5/Grade A filling rooms (two vial lines and one syringe), two large-scale lyophilization systems, two formulation suites, a terminal sterilizer, and final packaging capabilities. Those capabilities continue to expand in Camden with the addition of a new state-of-the-art groninger® FlexPro 50 high-speed fill line that uses isolator-based technology for aseptic processing of pre-sterilized syringes, cartridges, and vials.
Our Winnipeg, Manitoba, Canada site houses a state-of-the-art Cytiva® SA25 Aseptic Filling Workcell, providing clients with a high level of sterility assurance through an automated and gloveless handling, filling isolator, and closing process, designed to minimize line losses. Emergent was the first to bring the Cytiva SA25 online for a commercial product.
Non-viral